| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flow Cytometry | 62 | 2022 | 3033 | 3.490 |
Why?
|
| Immunophenotyping | 55 | 2022 | 1681 | 3.440 |
Why?
|
| Neoplasm, Residual | 45 | 2024 | 1656 | 2.990 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 34 | 2024 | 2796 | 2.110 |
Why?
|
| Bone Marrow | 22 | 2022 | 2358 | 1.930 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2023 | 482 | 1.580 |
Why?
|
| Leukemia, Myeloid, Acute | 33 | 2023 | 6915 | 1.570 |
Why?
|
| Lymphoma, B-Cell | 7 | 2023 | 895 | 1.470 |
Why?
|
| Antigens, CD | 15 | 2017 | 1385 | 1.290 |
Why?
|
| B-Lymphocytes | 9 | 2021 | 1294 | 1.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 47 | 2023 | 15862 | 1.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 17 | 2023 | 2390 | 0.960 |
Why?
|
| Immunoglobulin lambda-Chains | 3 | 2021 | 41 | 0.900 |
Why?
|
| Lymphoma, T-Cell | 8 | 2017 | 361 | 0.900 |
Why?
|
| Philadelphia Chromosome | 16 | 2023 | 793 | 0.870 |
Why?
|
| Plasma Cells | 5 | 2015 | 192 | 0.770 |
Why?
|
| Multiple Myeloma | 6 | 2021 | 2138 | 0.750 |
Why?
|
| Aged | 111 | 2024 | 70117 | 0.720 |
Why?
|
| Middle Aged | 122 | 2024 | 86204 | 0.720 |
Why?
|
| Precursor Cells, B-Lymphoid | 2 | 2019 | 35 | 0.700 |
Why?
|
| Adult | 118 | 2024 | 77950 | 0.700 |
Why?
|
| Vincristine | 18 | 2023 | 1511 | 0.650 |
Why?
|
| Leukemia, Hairy Cell | 6 | 2022 | 115 | 0.640 |
Why?
|
| Rituximab | 18 | 2022 | 1528 | 0.640 |
Why?
|
| Lymphoma, Mantle-Cell | 5 | 2022 | 713 | 0.620 |
Why?
|
| Antibodies, Bispecific | 4 | 2023 | 246 | 0.620 |
Why?
|
| Humans | 188 | 2024 | 261506 | 0.600 |
Why?
|
| Cyclophosphamide | 24 | 2023 | 3001 | 0.590 |
Why?
|
| Leukemia, B-Cell | 2 | 2014 | 117 | 0.590 |
Why?
|
| Male | 120 | 2021 | 123000 | 0.570 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 305 | 0.570 |
Why?
|
| Remission Induction | 23 | 2023 | 3569 | 0.560 |
Why?
|
| Aged, 80 and over | 63 | 2022 | 29902 | 0.560 |
Why?
|
| Prognosis | 37 | 2023 | 21713 | 0.560 |
Why?
|
| Mastocytosis, Systemic | 2 | 2014 | 110 | 0.540 |
Why?
|
| Biomarkers, Tumor | 19 | 2021 | 10331 | 0.530 |
Why?
|
| Chromosome Aberrations | 8 | 2021 | 1960 | 0.530 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2020 | 54 | 0.520 |
Why?
|
| Mast Cells | 2 | 2014 | 223 | 0.520 |
Why?
|
| Recurrence | 20 | 2024 | 4758 | 0.500 |
Why?
|
| Female | 114 | 2021 | 141928 | 0.500 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 5 | 2018 | 63 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2021 | 3251 | 0.490 |
Why?
|
| Gene Rearrangement | 6 | 2021 | 783 | 0.490 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 3 | 2020 | 106 | 0.480 |
Why?
|
| Dexamethasone | 16 | 2023 | 1450 | 0.460 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2020 | 387 | 0.450 |
Why?
|
| Doxorubicin | 17 | 2023 | 3005 | 0.440 |
Why?
|
| Bone Marrow Cells | 9 | 2016 | 943 | 0.420 |
Why?
|
| Mycosis Fungoides | 5 | 2020 | 320 | 0.420 |
Why?
|
| Mutation | 16 | 2021 | 15179 | 0.420 |
Why?
|
| Cladribine | 5 | 2018 | 233 | 0.420 |
Why?
|
| Young Adult | 43 | 2024 | 21445 | 0.410 |
Why?
|
| Primary Myelofibrosis | 6 | 2017 | 831 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2022 | 6550 | 0.400 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2020 | 560 | 0.390 |
Why?
|
| Sezary Syndrome | 4 | 2020 | 159 | 0.390 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 362 | 0.390 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5112 | 0.380 |
Why?
|
| Splenic Neoplasms | 4 | 2017 | 119 | 0.380 |
Why?
|
| Waldenstrom Macroglobulinemia | 3 | 2014 | 273 | 0.380 |
Why?
|
| Antigens, CD7 | 2 | 2020 | 23 | 0.370 |
Why?
|
| Immunohistochemistry | 16 | 2018 | 7548 | 0.370 |
Why?
|
| Translocation, Genetic | 5 | 2021 | 1245 | 0.370 |
Why?
|
| Monitoring, Physiologic | 2 | 2015 | 502 | 0.370 |
Why?
|
| Receptors, Cytokine | 4 | 2021 | 176 | 0.360 |
Why?
|
| Myelodysplastic Syndromes | 7 | 2019 | 2979 | 0.350 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2016 | 2527 | 0.350 |
Why?
|
| Adolescent | 43 | 2021 | 31252 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 7 | 2014 | 864 | 0.340 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2021 | 49 | 0.330 |
Why?
|
| Immunoglobulin Heavy Chains | 3 | 2021 | 247 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 3976 | 0.320 |
Why?
|
| Disease-Free Survival | 20 | 2023 | 10001 | 0.320 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2023 | 923 | 0.310 |
Why?
|
| Body Fluids | 1 | 2008 | 125 | 0.310 |
Why?
|
| Stem Cell Transplantation | 5 | 2018 | 1360 | 0.310 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2019 | 83 | 0.300 |
Why?
|
| Pyrimidines | 7 | 2019 | 3518 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2016 | 1493 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2022 | 2291 | 0.300 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2020 | 105 | 0.300 |
Why?
|
| Hematologic Neoplasms | 4 | 2021 | 1870 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2016 | 810 | 0.290 |
Why?
|
| Lymphoma | 2 | 2005 | 1467 | 0.290 |
Why?
|
| Janus Kinase 2 | 5 | 2017 | 679 | 0.290 |
Why?
|
| Antigens, CD34 | 5 | 2022 | 593 | 0.280 |
Why?
|
| Cytarabine | 8 | 2022 | 1973 | 0.270 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 771 | 0.270 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 95 | 0.270 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 6 | 2016 | 173 | 0.260 |
Why?
|
| Adenine | 7 | 2023 | 631 | 0.260 |
Why?
|
| Induction Chemotherapy | 6 | 2019 | 669 | 0.260 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2022 | 430 | 0.250 |
Why?
|
| Pyrazoles | 3 | 2019 | 1471 | 0.250 |
Why?
|
| Skin Neoplasms | 5 | 2021 | 4654 | 0.250 |
Why?
|
| Pyridazines | 2 | 2018 | 293 | 0.250 |
Why?
|
| Diagnosis, Differential | 12 | 2022 | 4744 | 0.250 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2021 | 2232 | 0.250 |
Why?
|
| Leukemia | 3 | 2022 | 1635 | 0.250 |
Why?
|
| Immunoconjugates | 2 | 2018 | 279 | 0.240 |
Why?
|
| Follow-Up Studies | 14 | 2023 | 14889 | 0.240 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 4988 | 0.240 |
Why?
|
| Treatment Outcome | 28 | 2022 | 32848 | 0.240 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2013 | 1094 | 0.240 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2018 | 480 | 0.240 |
Why?
|
| Lymphoma, AIDS-Related | 4 | 2005 | 70 | 0.240 |
Why?
|
| Transplantation Conditioning | 4 | 2016 | 2238 | 0.240 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 846 | 0.240 |
Why?
|
| CD3 Complex | 3 | 2020 | 314 | 0.220 |
Why?
|
| Survival Rate | 11 | 2021 | 12221 | 0.220 |
Why?
|
| Imidazoles | 3 | 2018 | 999 | 0.220 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2024 | 122 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2018 | 217 | 0.220 |
Why?
|
| Methotrexate | 8 | 2023 | 999 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 755 | 0.220 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2021 | 173 | 0.220 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3230 | 0.210 |
Why?
|
| Cell Count | 4 | 2022 | 508 | 0.210 |
Why?
|
| Sensitivity and Specificity | 6 | 2014 | 4971 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.210 |
Why?
|
| Blast Crisis | 2 | 2016 | 557 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 1586 | 0.200 |
Why?
|
| CD5 Antigens | 3 | 2014 | 112 | 0.200 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2014 | 31 | 0.200 |
Why?
|
| Azacitidine | 3 | 2018 | 1149 | 0.200 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2016 | 426 | 0.200 |
Why?
|
| Retrospective Studies | 21 | 2023 | 37905 | 0.200 |
Why?
|
| Thiazoles | 4 | 2014 | 726 | 0.200 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2016 | 1146 | 0.200 |
Why?
|
| T-Lymphocytes | 10 | 2016 | 3869 | 0.200 |
Why?
|
| Midwestern United States | 1 | 2020 | 18 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2018 | 6207 | 0.190 |
Why?
|
| Burkitt Lymphoma | 2 | 2022 | 335 | 0.190 |
Why?
|
| Leukemia, Biphenotypic, Acute | 2 | 2019 | 52 | 0.190 |
Why?
|
| Myeloproliferative Disorders | 2 | 2018 | 767 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2018 | 1249 | 0.190 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2018 | 801 | 0.190 |
Why?
|
| Cytogenetic Analysis | 3 | 2018 | 568 | 0.190 |
Why?
|
| Trisomy | 3 | 2016 | 231 | 0.180 |
Why?
|
| Antineoplastic Agents | 14 | 2019 | 14289 | 0.180 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2015 | 294 | 0.180 |
Why?
|
| Piperidines | 6 | 2022 | 1035 | 0.180 |
Why?
|
| Antigens, CD20 | 3 | 2012 | 206 | 0.180 |
Why?
|
| DNA Mutational Analysis | 4 | 2018 | 2283 | 0.180 |
Why?
|
| Simian virus 40 | 4 | 2005 | 137 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2018 | 10035 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2022 | 199 | 0.180 |
Why?
|
| Lymphoma, Follicular | 3 | 2016 | 587 | 0.170 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2019 | 46 | 0.170 |
Why?
|
| Immunologic Factors | 3 | 2015 | 649 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 673 | 0.170 |
Why?
|
| Vidarabine | 6 | 2021 | 1341 | 0.170 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2018 | 37 | 0.160 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2020 | 155 | 0.160 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 76 | 0.160 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 3472 | 0.160 |
Why?
|
| Receptors, CCR4 | 2 | 2015 | 34 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 1664 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2018 | 104 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 197 | 0.160 |
Why?
|
| Staining and Labeling | 3 | 2015 | 429 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 3343 | 0.150 |
Why?
|
| SOXC Transcription Factors | 1 | 2017 | 53 | 0.150 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2017 | 41 | 0.150 |
Why?
|
| CD59 Antigens | 2 | 2014 | 11 | 0.150 |
Why?
|
| Neoplasm Staging | 8 | 2016 | 13658 | 0.150 |
Why?
|
| Neprilysin | 5 | 2010 | 66 | 0.150 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2014 | 167 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2018 | 1823 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2018 | 254 | 0.150 |
Why?
|
| Mouth Neoplasms | 2 | 2019 | 713 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 120 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2005 | 1039 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 1756 | 0.140 |
Why?
|
| Single-Chain Antibodies | 1 | 2017 | 62 | 0.140 |
Why?
|
| Antibodies | 2 | 2018 | 838 | 0.140 |
Why?
|
| Sulfonamides | 3 | 2021 | 1823 | 0.140 |
Why?
|
| Histiocytosis | 2 | 2015 | 54 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 461 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 8 | 2017 | 3203 | 0.140 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 107 | 0.140 |
Why?
|
| Salvage Therapy | 6 | 2023 | 2054 | 0.140 |
Why?
|
| Herpes Simplex | 1 | 2017 | 95 | 0.140 |
Why?
|
| Methylation | 1 | 2017 | 597 | 0.140 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2015 | 24 | 0.130 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 2 | 2013 | 53 | 0.130 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 76 | 0.130 |
Why?
|
| Bursitis | 1 | 2015 | 10 | 0.130 |
Why?
|
| Killer Cells, Natural | 2 | 2018 | 904 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 366 | 0.130 |
Why?
|
| Neutropenia | 2 | 2019 | 968 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 1033 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2020 | 16273 | 0.130 |
Why?
|
| Phycoerythrin | 1 | 2014 | 4 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2018 | 4938 | 0.130 |
Why?
|
| CD2 Antigens | 1 | 2014 | 31 | 0.130 |
Why?
|
| Tetraspanin 30 | 1 | 2014 | 14 | 0.130 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 20 | 0.130 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2014 | 52 | 0.130 |
Why?
|
| Megakaryocytes | 1 | 2015 | 104 | 0.130 |
Why?
|
| Castleman Disease | 1 | 2015 | 69 | 0.130 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2016 | 181 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2012 | 1242 | 0.120 |
Why?
|
| Transplantation, Homologous | 4 | 2017 | 2843 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 295 | 0.120 |
Why?
|
| Phenotype | 7 | 2018 | 6295 | 0.120 |
Why?
|
| Shoulder Joint | 1 | 2015 | 82 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 669 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 228 | 0.120 |
Why?
|
| Cytochrome c Group | 3 | 1994 | 71 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 221 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2009 | 690 | 0.120 |
Why?
|
| Macrophage Activation | 1 | 2014 | 148 | 0.120 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 162 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 245 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 6 | 2014 | 4367 | 0.110 |
Why?
|
| Child | 15 | 2020 | 29154 | 0.110 |
Why?
|
| Immunoglobulin kappa-Chains | 3 | 2012 | 73 | 0.110 |
Why?
|
| DNA, Viral | 3 | 2005 | 694 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2012 | 479 | 0.110 |
Why?
|
| CD11a Antigen | 1 | 2012 | 15 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2014 | 161 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 5539 | 0.110 |
Why?
|
| Thrombocythemia, Essential | 1 | 2014 | 162 | 0.110 |
Why?
|
| Antigens, Neoplasm | 3 | 2008 | 1506 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3552 | 0.110 |
Why?
|
| Europe | 3 | 2021 | 649 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 3 | 2010 | 125 | 0.110 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 384 | 0.110 |
Why?
|
| CD18 Antigens | 1 | 2012 | 83 | 0.110 |
Why?
|
| In Situ Hybridization | 3 | 2017 | 1037 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 1443 | 0.100 |
Why?
|
| Facial Dermatoses | 1 | 2012 | 26 | 0.100 |
Why?
|
| Polycythemia Vera | 1 | 2014 | 238 | 0.100 |
Why?
|
| Family | 1 | 2016 | 736 | 0.100 |
Why?
|
| Patient Safety | 1 | 2018 | 649 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2016 | 769 | 0.100 |
Why?
|
| Pancytopenia | 1 | 2012 | 120 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2017 | 166 | 0.100 |
Why?
|
| Immunotherapy | 3 | 2019 | 3341 | 0.100 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 4892 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2015 | 398 | 0.100 |
Why?
|
| Chromosome Banding | 1 | 2011 | 256 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 5437 | 0.100 |
Why?
|
| Biomarkers | 7 | 2019 | 5047 | 0.100 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4557 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 317 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2015 | 355 | 0.090 |
Why?
|
| Bone Marrow Examination | 3 | 2016 | 153 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2018 | 1664 | 0.090 |
Why?
|
| Survival Analysis | 6 | 2020 | 9180 | 0.090 |
Why?
|
| Prospective Studies | 7 | 2022 | 12873 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2016 | 317 | 0.090 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2010 | 34 | 0.090 |
Why?
|
| Tetraspanin 28 | 1 | 2009 | 13 | 0.090 |
Why?
|
| Biopsy | 5 | 2018 | 3443 | 0.090 |
Why?
|
| Chemokine CCL5 | 2 | 2009 | 71 | 0.090 |
Why?
|
| Antigens, CD19 | 3 | 2012 | 577 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2014 | 301 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 347 | 0.090 |
Why?
|
| Platelet Count | 2 | 2015 | 490 | 0.090 |
Why?
|
| Dendritic Cells | 3 | 2021 | 1085 | 0.090 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2009 | 30 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2195 | 0.090 |
Why?
|
| Lymphocyte Count | 3 | 2019 | 486 | 0.090 |
Why?
|
| HIV Infections | 4 | 2003 | 2134 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 4757 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2011 | 1234 | 0.090 |
Why?
|
| Time Factors | 7 | 2020 | 12926 | 0.090 |
Why?
|
| Dasatinib | 4 | 2014 | 862 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2011 | 269 | 0.080 |
Why?
|
| Breast Implantation | 1 | 2012 | 228 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 2173 | 0.080 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2008 | 52 | 0.080 |
Why?
|
| Basophils | 1 | 2008 | 38 | 0.080 |
Why?
|
| Histiocytes | 2 | 2015 | 94 | 0.080 |
Why?
|
| Proto-Oncogenes | 1 | 2008 | 202 | 0.080 |
Why?
|
| RNA, Messenger | 5 | 2013 | 6150 | 0.080 |
Why?
|
| Anemia | 1 | 2014 | 689 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 1062 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5178 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 1350 | 0.080 |
Why?
|
| Macrophages | 1 | 2014 | 1304 | 0.080 |
Why?
|
| Lymph Nodes | 5 | 2017 | 2967 | 0.080 |
Why?
|
| Bone Marrow Diseases | 1 | 2008 | 177 | 0.080 |
Why?
|
| DNA-Binding Proteins | 4 | 2010 | 4821 | 0.080 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2007 | 15 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 7551 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8873 | 0.070 |
Why?
|
| Breast Implants | 1 | 2012 | 391 | 0.070 |
Why?
|
| World Health Organization | 1 | 2008 | 316 | 0.070 |
Why?
|
| Infectious Mononucleosis | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 875 | 0.070 |
Why?
|
| Disease Progression | 4 | 2020 | 6682 | 0.070 |
Why?
|
| Orbital Diseases | 1 | 2007 | 118 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2011 | 2086 | 0.070 |
Why?
|
| Tibial Fractures | 1 | 1986 | 58 | 0.070 |
Why?
|
| Molecular Sequence Data | 8 | 2009 | 6089 | 0.070 |
Why?
|
| Knee Injuries | 1 | 1986 | 63 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 383 | 0.070 |
Why?
|
| Hashimoto Disease | 1 | 2006 | 19 | 0.070 |
Why?
|
| Combined Modality Therapy | 5 | 2018 | 8865 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 1299 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 269 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2008 | 731 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2005 | 109 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 2638 | 0.070 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2005 | 110 | 0.070 |
Why?
|
| Histiocytosis, Sinus | 1 | 2006 | 86 | 0.070 |
Why?
|
| Karyotyping | 3 | 2015 | 1022 | 0.070 |
Why?
|
| Idarubicin | 2 | 2018 | 446 | 0.060 |
Why?
|
| Prednisone | 4 | 2013 | 984 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 1371 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 1375 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2017 | 2359 | 0.060 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 102 | 0.060 |
Why?
|
| Asparaginase | 2 | 2016 | 184 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2009 | 661 | 0.060 |
Why?
|
| Risk Factors | 6 | 2018 | 17523 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2009 | 2074 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2018 | 9244 | 0.060 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 14551 | 0.060 |
Why?
|
| Texas | 5 | 2018 | 6311 | 0.060 |
Why?
|
| HIV-1 | 3 | 2005 | 653 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2009 | 1016 | 0.060 |
Why?
|
| Lymphocyte Activation | 4 | 2009 | 1688 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 666 | 0.060 |
Why?
|
| Base Sequence | 6 | 2009 | 4917 | 0.060 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2022 | 38 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2019 | 1544 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2008 | 5270 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1993 | 182 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2015 | 702 | 0.050 |
Why?
|
| Peptides | 3 | 1993 | 1479 | 0.050 |
Why?
|
| JC Virus | 1 | 2002 | 43 | 0.050 |
Why?
|
| Stem Cell Factor | 2 | 2015 | 87 | 0.050 |
Why?
|
| Animals | 9 | 2017 | 59536 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.050 |
Why?
|
| Mercaptopurine | 2 | 2014 | 130 | 0.050 |
Why?
|
| Transcriptome | 2 | 2023 | 1859 | 0.050 |
Why?
|
| Campylobacter fetus | 1 | 2001 | 4 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 1290 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2001 | 20 | 0.050 |
Why?
|
| Campylobacter Infections | 1 | 2001 | 36 | 0.050 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 2012 | 36 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 2231 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 750 | 0.050 |
Why?
|
| Hypersplenism | 1 | 2001 | 23 | 0.050 |
Why?
|
| Amino Acid Sequence | 6 | 1994 | 4233 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 1217 | 0.050 |
Why?
|
| BK Virus | 1 | 2002 | 123 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2005 | 966 | 0.050 |
Why?
|
| Neoplasms, Mesothelial | 1 | 2000 | 6 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 489 | 0.050 |
Why?
|
| Genotype | 1 | 2008 | 4109 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2017 | 11965 | 0.050 |
Why?
|
| Splenomegaly | 2 | 2016 | 158 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2001 | 260 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 2483 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2004 | 731 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2006 | 548 | 0.040 |
Why?
|
| Cell Line | 4 | 2019 | 5114 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 2 | 2012 | 188 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2022 | 668 | 0.040 |
Why?
|
| Thymoma | 1 | 2003 | 246 | 0.040 |
Why?
|
| Imatinib Mesylate | 2 | 2013 | 1665 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2006 | 297 | 0.040 |
Why?
|
| United States | 4 | 2018 | 15433 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 423 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2009 | 406 | 0.040 |
Why?
|
| Cell Survival | 2 | 2015 | 3045 | 0.040 |
Why?
|
| Cysts | 1 | 2000 | 197 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 2055 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2001 | 362 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2000 | 223 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2018 | 72 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 750 | 0.040 |
Why?
|
| Antigens, Surface | 2 | 2014 | 295 | 0.040 |
Why?
|
| Liposomes | 1 | 2020 | 684 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2018 | 75 | 0.040 |
Why?
|
| Benzamides | 2 | 2013 | 1832 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2019 | 165 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2000 | 262 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2018 | 334 | 0.040 |
Why?
|
| Germinal Center | 2 | 2010 | 161 | 0.040 |
Why?
|
| Incidence | 4 | 2016 | 5673 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 2422 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 465 | 0.040 |
Why?
|
| Codon | 1 | 2017 | 241 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 409 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2018 | 174 | 0.040 |
Why?
|
| Osteoblasts | 1 | 2019 | 370 | 0.040 |
Why?
|
| Therapeutics | 1 | 2016 | 34 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2017 | 7226 | 0.040 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2016 | 67 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2016 | 69 | 0.040 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.030 |
Why?
|
| Fibroblasts | 3 | 2019 | 1682 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 275 | 0.030 |
Why?
|
| Enterotoxins | 2 | 1993 | 112 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 55 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 47 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 2488 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 43 | 0.030 |
Why?
|
| Core Binding Factors | 1 | 2016 | 112 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 3639 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 4298 | 0.030 |
Why?
|
| Gene Expression | 2 | 2019 | 3570 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 644 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 1374 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2015 | 54 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 665 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 234 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 2015 | 185 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 116 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 275 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2014 | 6100 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 266 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 68 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 978 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 650 | 0.030 |
Why?
|
| Piperazines | 2 | 2013 | 2101 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 684 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1429 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2005 | 2104 | 0.030 |
Why?
|
| Pentostatin | 1 | 2014 | 119 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 338 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 289 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 380 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 155 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 1390 | 0.030 |
Why?
|
| Splenectomy | 1 | 2014 | 158 | 0.030 |
Why?
|
| Apoptosis | 2 | 2019 | 7591 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 1914 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 15694 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2016 | 4078 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2014 | 301 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 299 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 202 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 1082 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 905 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 471 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2017 | 441 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 344 | 0.030 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2012 | 11 | 0.030 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2012 | 13 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2012 | 38 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1084 | 0.030 |
Why?
|
| Antigens | 1 | 1993 | 292 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 43 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2005 | 747 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 1910 | 0.030 |
Why?
|
| Color | 1 | 2012 | 66 | 0.030 |
Why?
|
| Models, Structural | 1 | 1992 | 103 | 0.030 |
Why?
|
| Columbidae | 1 | 1992 | 23 | 0.030 |
Why?
|
| Moths | 1 | 1992 | 36 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 11538 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1993 | 1258 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1890 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 1992 | 74 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 1992 | 91 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1992 | 300 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 665 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 719 | 0.030 |
Why?
|
| Quinolines | 1 | 2015 | 383 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1992 | 293 | 0.030 |
Why?
|
| Peroxidase | 1 | 2012 | 132 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2012 | 202 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 13310 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 261 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2012 | 220 | 0.020 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 182 | 0.020 |
Why?
|
| Kinetics | 2 | 1992 | 2049 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 173 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1046 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3981 | 0.020 |
Why?
|
| Viral Load | 2 | 2003 | 493 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2010 | 33 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 899 | 0.020 |
Why?
|
| CD13 Antigens | 1 | 2010 | 36 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 1382 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2010 | 58 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2010 | 76 | 0.020 |
Why?
|
| Device Removal | 1 | 2012 | 337 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2010 | 83 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 778 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 607 | 0.020 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2009 | 27 | 0.020 |
Why?
|
| Chemokine CXCL13 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Cell Size | 1 | 2010 | 136 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 137 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 102 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 3536 | 0.020 |
Why?
|
| Granulocytes | 1 | 2010 | 224 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Cricetinae | 2 | 2004 | 706 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 2315 | 0.020 |
Why?
|
| CD55 Antigens | 1 | 2008 | 17 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 1226 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.020 |
Why?
|
| Tryptases | 1 | 2008 | 48 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 1988 | 67 | 0.020 |
Why?
|
| China | 1 | 2010 | 606 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2008 | 37 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2009 | 682 | 0.020 |
Why?
|
| Proteomics | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 760 | 0.020 |
Why?
|
| Gene Library | 1 | 2009 | 294 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1439 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3821 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1678 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1994 | 1271 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1546 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 5061 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6009 | 0.020 |
Why?
|
| Transfection | 1 | 1993 | 2944 | 0.020 |
Why?
|
| Orbital Pseudotumor | 1 | 2007 | 13 | 0.020 |
Why?
|
| Lymphokines | 1 | 1988 | 272 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2011 | 584 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 612 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 1994 | 4143 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3719 | 0.020 |
Why?
|
| Binding Sites | 1 | 1992 | 2171 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 1643 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2054 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 275 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2009 | 574 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 582 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2008 | 315 | 0.020 |
Why?
|
| Mice | 4 | 2017 | 34495 | 0.020 |
Why?
|
| Endothelium | 1 | 1987 | 158 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7702 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2006 | 41 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 650 | 0.020 |
Why?
|
| CD52 Antigen | 1 | 2005 | 46 | 0.020 |
Why?
|
| Receptors, IgE | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2045 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 2316 | 0.020 |
Why?
|
| Monocytes | 1 | 2010 | 788 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 5710 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2809 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2005 | 202 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 2004 | 48 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2004 | 114 | 0.020 |
Why?
|
| Clone Cells | 1 | 2006 | 555 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 3890 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 1351 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2508 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 1183 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2006 | 355 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 777 | 0.010 |
Why?
|
| Poliovirus Vaccines | 1 | 2003 | 16 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 72 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 61 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 4804 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2002 | 32 | 0.010 |
Why?
|
| Polyomavirus Infections | 1 | 2003 | 139 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 224 | 0.010 |
Why?
|
| Splenic Infarction | 1 | 2001 | 14 | 0.010 |
Why?
|
| Piperacillin | 1 | 2001 | 29 | 0.010 |
Why?
|
| Erythromycin | 1 | 2001 | 22 | 0.010 |
Why?
|
| Leucovorin | 1 | 2002 | 332 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 144 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 1904 | 0.010 |
Why?
|
| Bleomycin | 1 | 2002 | 467 | 0.010 |
Why?
|
| Ceftazidime | 1 | 2001 | 57 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 218 | 0.010 |
Why?
|
| Penicillins | 1 | 2001 | 143 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2003 | 671 | 0.010 |
Why?
|
| Cephalosporins | 1 | 2001 | 148 | 0.010 |
Why?
|
| Quinolones | 1 | 2001 | 160 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 1399 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4549 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 350 | 0.010 |
Why?
|
| Desmin | 1 | 1998 | 63 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 5159 | 0.010 |
Why?
|
| Kidney | 1 | 1987 | 2146 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 2522 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 686 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 4053 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2000 | 712 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2000 | 519 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2000 | 779 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2002 | 1320 | 0.010 |
Why?
|
| Stromal Cells | 1 | 1998 | 825 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cell Division | 1 | 1998 | 2489 | 0.010 |
Why?
|
| Hybridomas | 1 | 1993 | 75 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1994 | 170 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1994 | 170 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1879 | 0.010 |
Why?
|
| CHO Cells | 1 | 1993 | 311 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1994 | 5637 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 284 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1993 | 611 | 0.010 |
Why?
|
| Pain | 1 | 2000 | 1658 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1993 | 931 | 0.010 |
Why?
|
| Epitopes | 1 | 1993 | 685 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1993 | 548 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2992 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1988 | 354 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1993 | 1694 | 0.000 |
Why?
|
| Immunoassay | 1 | 1988 | 216 | 0.000 |
Why?
|
| Sulfur Radioisotopes | 1 | 1987 | 26 | 0.000 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1987 | 65 | 0.000 |
Why?
|
| Fibronectins | 1 | 1987 | 197 | 0.000 |
Why?
|
| Methionine | 1 | 1987 | 159 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1987 | 629 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 2000 | 3022 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1988 | 1213 | 0.000 |
Why?
|
| Neoplasms | 1 | 2012 | 15193 | 0.000 |
Why?
|
| Epithelium | 1 | 1987 | 720 | 0.000 |
Why?
|
| DNA | 1 | 1988 | 2693 | 0.000 |
Why?
|